title: Clinical correlates of hemoconcentration during hospitalization for acute decompensated heart failure.
abstract: BACKGROUND
  Hemoconcentration has been proposed as a putative biomarker of effective decongestion therapy in heart failure patients. The prevalence and clinical correlates of hemoconcentration in hospitalized patients with acute decompensated heart failure (ADHF) have not been previously described.
  
  
  RESULTS
  We retrospectively reviewed paired values of hemoglobin at admission and discharge to identify evidence of hemoconcentration in 295 subjects hospitalized with ADHF and determined the association between hemoconcentration and risk of worsening renal function and survival. Subjects with hemoconcentration (n = 75) received higher diuretic doses and demonstrated greater weight loss during hospitalization when compared with subjects without hemoconcentration (median [IQR] loop diuretic dose 180 (120) versus 160 (150) mg, P = .014; mean ± SD weight loss 4.0 ± 3.1 versus 2.2 ± 3.1 kg, P < .001). In univariate analysis, hemoconcentration was associated with increased risk of worsening renal function (odds ratio 2.34, 95% CI 1.27-4.30, P = .006), but decreased risk of all-cause mortality (hazard ratio 0.53, 95% CI 0.29-0.96, P = .035). In multivariate analysis, hemoconcentration remained independently associated with worsening renal function, but not mortality.
  
  
  CONCLUSIONS
  Hemoconcentration is significantly associated with increased diuretic dose, greater weight loss, and increased risk of worsening renal function during hospitalization. Hemoconcentration was significantly associated with mortality in univariate analysis, but not in multivariate analysis.
authors: Leon H. Charney Division of Cardiology, Department of Medicine, New York University Langone Medical Center, New York, NY, USA.
authors: Carlos
authors: C
authors: Davila
authors: Alex
authors: A
authors: Reyentovich
authors: Stuart D
authors: SD
authors: Katz
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D016001:Confidence Intervals; D018450:Disease Progression; D004232:Diuretics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D045604:Extracellular Fluid / Q000378:metabolism; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D006454:Hemoglobins / Q000378:metabolism*; D006760:Hospitalization; D006801:Humans; D007668:Kidney / Q000502:physiology*; D008297:Male; D015999:Multivariate Analysis; D011379:Prognosis; D012189:Retrospective Studies; D049994:Sodium Potassium Chloride Symporter Inhibitors / Q000627:therapeutic use; D013223:Statistics as Topic; D016896:Treatment Outcome; D015431:Weight Loss / Q000502:physiology
chemical_list: D015415:Biomarkers; D004232:Diuretics; D006454:Hemoglobins; D049994:Sodium Potassium Chloride Symporter Inhibitors